Neurocrine backs CAH-focused supplement in JCEM

SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has sponsored a supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM) focusing on classic congenital adrenal hyperplasia (CAH), a rare genetic condition. The supplement, titled "Challenges and Opportunities in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency Throughout the Lifetime," features eight review articles that delve into the multifaceted challenges faced by individuals with classic CAH.

According to Dr. Richard Auchus, M.D., Ph.D., Principal Investigator at the University of Michigan, the publication captures the complex nature of CAH and its management. He highlighted the limitations of traditional glucocorticoid treatments, especially in areas with fewer resources, which can lead to significant disease burden and poor patient outcomes. Dr. Auchus expressed optimism for new treatments like corticotropin-releasing factor type 1 receptor antagonists, which could offer more personalized care and better control of androgen levels with fewer glucocorticoid-related health consequences.

The JCEM supplement, authored by leading endocrinologists and researchers, provides insights into the pathophysiology, clinical manifestations, and treatment challenges of classic CAH. It also discusses the psychosocial impact of the condition and advances in treatment, including CRENESSITY™ (crinecerfont), an oral medication developed by Neurocrine Biosciences. The company's strong focus on medical innovations has contributed to impressive 25.7% revenue growth over the last twelve months, with a healthy gross margin of 68%. For detailed financial analysis and additional insights, investors can access the comprehensive Pro Research Report available on InvestingPro. CRENESSITY is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone and adrenal androgen production, potentially allowing for reduced glucocorticoid dosages.

Neurocrine Biosciences' Chief Medical (TASE:PMCN) Officer, Eiry W. Roberts, M.D., expressed the company's commitment to supporting educational content that empowers patients, caregivers, and healthcare providers in managing CAH.

CAH is characterized by an enzyme deficiency affecting adrenal steroid hormone production. The majority of cases are due to mutations in the CYP21A2 gene, leading to 21-hydroxylase deficiency. Without treatment, CAH can lead to severe health issues, including salt wasting and dehydration.

CRENESSITY is available in capsule and oral solution forms and is prescribed alongside glucocorticoids to control androgen levels in adults and children aged four and older with classic CAH. The medication has been shown to enable lower doses of glucocorticoids, which are traditionally administered at higher levels to manage the condition.

This educational supplement is based on a press release statement from Neurocrine Biosciences and aims to enhance clinical practice and patient care for those affected by classic CAH. According to InvestingPro analysis, the company appears undervalued at current levels, with analysts projecting continued net income growth. InvestingPro subscribers have access to 12 additional investment tips and detailed valuation metrics for NBIX, helping investors make more informed decisions about this promising biotech company.

In other recent news, Neurocrine Biosciences has made significant strides with the FDA approval and subsequent launch of its novel treatment, Crenessity, for congenital adrenal hyperplasia (CAH). This development aligns with the company's impressive 25.7% revenue growth over the past year. Analysts from Piper Sandler, Goldman Sachs, and H.C. Wainwright have maintained positive ratings on Neurocrine Biosciences, reflecting confidence in the company's financial outlook and the market potential of Crenessity.

Oppenheimer has reiterated its Outperform rating on the company, emphasizing the potential of the robust pipeline which includes Phase 3 trials for NBI-568 and osavampator expected in the first half of 2025. The company has also expanded its salesforce for Ingrezza, a treatment for tardive dyskinesia (TD), aiming to increase its reach within the approximately 800,000-patient market.

These recent developments highlight Neurocrine Biosciences' commitment to developing effective treatments for neurological and endocrine-related diseases and disorders. The company's strong financial health is evident in its impressive 25.7% revenue growth and robust gross profit margin of 68%. Piper Sandler's analysis forecasts that the peak U.S. sales potential for Crenessity could realistically reach between $800 million and $1 billion.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.